Inozyme Pharma Inc. Announces Delisting from Nasdaq and Deregistration of Shares Following Merger
I'm PortAI, I can summarize articles.
Inozyme Pharma Inc. has announced its delisting from Nasdaq and deregistration of shares following a merger, effective July 1, 2025. The company has requested Nasdaq to file a Form 25 with the SEC to remove its shares from listing and intends to file a Form 15 to terminate registration and suspend reporting obligations under the Securities Exchange Act of 1934. This marks a significant regulatory move in Inozyme's corporate trajectory post-merger.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments